Vision & Mission

Helping patients with safe, effective biologic drugs

Our aim and vision is to enable broad access to high quality, highly competitive biopharmaceuticals for the treatment of serious diseases.

Medicines of the future

Biosimilars are the drugs of the future. Through their proven efficacy, cost efficiency and high standard of quality, Biosimilar medicines are already making a major contribution towards enabling patient access to effective medical treatments.

Through our biosimilars, we will help not only patients around the world but also help to ease the financial strains on the world’s healthcare systems.

“Biological medicines are … complex and can be very expensive and time consuming to develop. This can limit patients’ access to such medicines, and can make it difficult for the healthcare system to afford them. Biosimilar medicines can improve patient access to such treatments.”

European Commission, Biosimilar Medicines: Information for Patients, 2016

Profitable and sustainable growth

Already today, Formycon is a significant player in the biosimilars market segment. Our goal now is to further strengthen this position and to become, as a leading independent developer of Biosimilar medicines, a major and truly global player.

Our strategic focus is on the “third wave” of biosimilars, meaning follow-on drugs to compete with established blockbuster biopharmaceuticals for which patent protection will begin expiring from the year 2020 onwards. Because Formycon began targeting these products at an early stage, the company is now uniquely positioned to lead the way into these new markets.

“The market is well positioned to achieve a robust growth in the coming decade … Based on a very comprehensive analysis, we have projected the market to be worth USD 32 billion worldwide by 2025.”

Research and Markets,Global Biosimilars Market Report, 2015 – 2025

Strong pipeline

Building on the specialized expertise and long experience of our team, as well as our successful established track record in biosimilar development, we are able to evaluate further potential and promising biosimilar candidates for our pipeline.

Because Formycon spans the entire value chain – from early analysis to technical-pharmaceutical development and clinical trials, all the way through to preparation and submission of dossiers for regulatory approval – we are able to offer our partners a complete, end-to-end drug development concept.

In its strong pipeline, Formycon already has four biosimilar candidates in clinical or pre-clinical development. We have already signed out-licensing partnership deals for two of these, FYB201 and FYB203, while a third, FYB202, has been transferred into a joint venture with a major partner.

FYB201, Lucentis®¹ biosimilar candidate

FYB202, Stelara®² biosimilar candidate

FYB203, Eylea®³ biosimilar candidate

FYB205, undisclosed

“In the coming year, biosimilars will play an increasingly important role in the treatment of serious diseases ... and in keeping our health care system affordable.”

German Federal Ministry of Health, Report on Results of Pharmaceutical Dialog, 2016

Latest news

July 1, 2019

Formycon Reports on Annual General Meeting 2019

Formycons shareholders followed the proposals of the Board of Management and the Supervisory Board and approved all resolutions proposed by the management with large majorities in each case.

June 26, 2019

Formycon Reports Further Course of Capital Measure

With the agreement dated June 26, 2019, Wendeln & Cie. KG, an asset management company of Mr. Peter Wendeln (anchor shareholder and long-standing member of the Supervisory Board of Formycon AG), acquired all rights from the certificate of subscription as well as the 577,397 shares in Formycon AG from the cash capital increase.

June 5, 2019

Formycon Publishes Figures for the First Quarter of 2019

The Group sales, including other earnings, as of March 31 of this year amount to EUR 9.5 million. Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to EUR 0.5 million. The operating result (EBIT) as well as the quarterly result totaled around EUR 0.2 Million. The reported sales revenues result from reimbursements for development work in the licensed-out projects or projects developed in partnership. For the 2019 fiscal year, revenues in the amount of approximately EUR 35.0 million are expected at the group level.

¹ Lucentis is a registered trademark of Genentech, Inc
² Stelara is a registered trademark of Johnson & Johnson
³ Eylea is a registered trademark of Regeneron Pharmaceuticals, Inc.